Midostaurin
About
Therapy type: Targeted therapy
Therapy strategy: FLT3 inhibition
Mappings
NCI Thesaurus: Midostaurin (ncit:C1872)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) | FLT3-ITD | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | FLT3 p.D835Y | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | FLT3 p.D835A | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | FLT3 p.D835E | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | FLT3 p.D835H | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | FLT3 p.D835N | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | FLT3 p.D835S | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | FLT3 p.D835V | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | FLT3 p.I836del | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (1) | CDK12 oncogenic variants | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin |